James A Schoeneck
CIK 1420987 · Interim President · last filed 2026-06-17
James A Schoeneck is an Interim President who has filed 75 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing, for KYNB, was dated Jun 17, 2026. Across all open-market trades the lifetime net is −$1.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $565 across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$565
6
75
-$1.79M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KYNB | Director | — | $6.97 | — | $0 | 1 | 2026-06-17 |
| CLDI | Director | 5,260 | $0.11 | $565 | $150.0K | 2 | 2025-08-25 |
| KYNTRA BIO, INC. (FGEN) Delisted | Director | 40,817 | $9.75 | $398.0K | -$1.20M | 28 | 2025-07-02 |
| Calidi Biotherapeutics, Inc. (CLDI.WS) Delisted | Director | 2,035,668 | $0.01 | $11.8K | $0 | 6 | 2024-10-15 |
| ANAB | Director | — | $52.11 | — | $0 | 2 | 2018-02-06 |
| Assertio Therapeutics, Inc (DEPO) Delisted | President and CEO | 495,105 | — | — | -$743.6K | 35 | 2017-02-10 |
Recent Filings
75 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-17 | KYNB | Grant (A) | — | $0 | EDGAR |
| 2025-08-25 | CLDI | Buy (P) | +75,000 | $150.0K | EDGAR |
| 2025-07-15 | CLDI | Grant (A) | — | $0 | EDGAR |
| 2025-07-02 | KYNTRA BIO, INC. (FGEN) Delisted | Buy (P) | +23,567 | $119.5K | EDGAR |
| 2025-06-06 | KYNTRA BIO, INC. (FGEN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-03-24 | KYNTRA BIO, INC. (FGEN) Delisted | Buy (P) | +300,000 | $105.0K | EDGAR |
| 2024-10-15 | Calidi Biotherapeutics, Inc. (CLDI.WS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-07-02 | Calidi Biotherapeutics, Inc. (CLDI.WS) Delisted | Grant (A) | +79,687 | $0 | EDGAR |
| 2024-07-02 | Calidi Biotherapeutics, Inc. (CLDI.WS) Delisted | Grant (A) | +28,207 | $0 | EDGAR |
| 2024-06-06 | KYNTRA BIO, INC. (FGEN) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.